Back to search

Article

Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression

2018-07-03

Abstract excerpt

<h4>Background</h4> Because human epidermal growth factor-like receptor (HER) 2 is expressed on the surface of human pancreatic carcinoma cells to varying degrees, trastuzumab, an anti-HER2 monoclonal antibody (mAb), is expected to exert antibody-dependent, natural killer (NK) cell-mediated cytotoxicity (ADCC) against the cells. However, some reports found that the effect of trastuzumab against human pancreatic c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
51646734-0757-5980-aa43-49db3b54d319
DOI
10.1101/361279
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expressionDOI 10.1101/361279
Subtype-specific HERV-K102 envelope is a novel serum immunosuppressive biomarker and therapeutic target of cancerSemantic proximity
Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity
Strength in Unity: a Dual Strategy to Restore NK Cell Cytotoxicity against Pancreatic Ductal AdenocarcinomaSemantic proximity
Engineering NKG2D ligand affinity transforms EGFR-targeted NK cell engagers into high-potency effectors against pancreatic cancerSemantic proximity
The arming of NK cells with Fc-engineered rituximab confers them specificity against CD20-expressing cellsSemantic proximity
Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.Semantic proximity
Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid LineageSemantic proximity
Novel CAR-T Cells Specifically Targeting Nectin4 Exhibit Effective Anti-Tumor Efficacy in Bladder Cancer Cell LinesSemantic proximity
Targeting CD137 enhances the efficacy of cetuximab.Semantic proximity
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2Semantic proximity
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.Semantic proximity
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Semantic proximity
Select a neighboring publication to make it the new centre.